Opendata, web and dolomites


Novel treatment of inflammatory diseases

Total Cost €


EC-Contrib. €






 NOTID project word cloud

Explore the words cloud of the NOTID project. It provides you a very rough idea of what is the project "NOTID" about.

block    destruction    full    pointed    treatment    twice    disease    thereby    organisation    woman    quality    men    tentative    time    extreme    constituted    create    designation    20    hold    world    inflammatory    inhibit    prevent    diagnosed    pharmaceuticals    potentially    patients    rheumatoid    inhibitors    economic    improvement    complementary    combined    salt    suppress    countries    fill    calculations    mechanism    life    introduction    stimulated    achievement    burden    global    poor    job    health       estimate    85    antibody    juvenile    bile    biologicals    onset    intends    market    usd    gap    leaders    disability    societal    therapeutic    alfa    ra    orphan    total    directed    biological    occurring    unable    prevalence    2014    strategy    age    tnf    adverse    concluded    immunosuppressants    immune    opinion    frequently    drug    diseases    lipase    enormous    ten    55    2019    idiopathic    50    responding    billion    children    serious    drugs    joint    arthritis    co    transient    lipum    risk    discovered   

Project "NOTID" data sheet

The following table provides information about the project.


Organization address
address: TVISTEVAGEN 48 C
city: UMEA
postcode: 907 36
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-12-01   to  2017-04-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    LIPUM AB SE (UMEA) coordinator 50˙000.00


 Project objective

LipUm has discovered a novel treatment of rheumatoid arthritis (RA) and potentially other inflammatory diseases by a unique therapeutic antibody directed towards the Bile Salt-Stimulated Lipase, which has been identified as a key target to block and thereby inhibit the inflammatory process and prevent joint destruction. The global prevalence of RA is 0.3-1%, and it is twice as common among woman than men, and the risk to develop the condition increases by age. Frequently, other serious diseases are co-occurring with RA and according to the World Health Organisation 50% of patients in developed countries are unable to hold a full-time job within ten years after disease onset. The societal economic burden due to the disease is thus enormous, while health economic calculations estimate the cost for pharmaceuticals to less than 20% of the total cost. Still, the drug market value growth between 2014 and 2019 is expected to increase by 55% to 30 billion USD. The introduction and use of biologicals such as the TNF-alfa inhibitors constituted a major achievement in the treatment, but with time it has also been concluded that 1/3 of patients are not responding and another 1/3 experience only a transient improvement. As these biologicals suppress the immune system such drugs should not be combined with other immunosuppressants, as it may create adverse health effects. Key opinion leaders have therefore pointed out the need for drugs that have a complementary therapeutic mechanism. This is the gap that LipUm intends to fill and a tentative strategy is to apply for a orphan drug designation for juvenile idiopathic arthritis that affect children, frequently with extreme disability and poor quality of life. As an orphan drug our unique biological more rapidly could contribute to improved treatment of the 85,000 children diagnosed with the disease in Europe.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NOTID" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NOTID" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PD_Pal (2019)

Palliative care in Parkinson’s disease

Read More  


Integrating and decentralising diabetes and hypertension services in Africa

Read More  

SELNET (2019)

Sarcoma as a model to improve diagnosis and clinical care of rare tumors through a European and Latin American multidisciplinary network

Read More